Invention Grant
US08394791B2 Crystalline, enantiomerically pure salt form of a beta-agonist, and the use thereof as a drug
失效
β激动剂的结晶，对映体纯盐形式及其作为药物的用途
- Patent Title: Crystalline, enantiomerically pure salt form of a beta-agonist, and the use thereof as a drug
- Patent Title (中): β激动剂的结晶，对映体纯盐形式及其作为药物的用途
-
Application No.: US12918374Application Date: 2009-02-17
-
Publication No.: US08394791B2Publication Date: 2013-03-12
- Inventor: Ulrike Werthmann , Marco Santagostino , Adil Duran
- Applicant: Ulrike Werthmann , Marco Santagostino , Adil Duran
- Applicant Address: DE Ingelheim am Rhein
- Assignee: Boehringer Ingelheim International GmbH
- Current Assignee: Boehringer Ingelheim International GmbH
- Current Assignee Address: DE Ingelheim am Rhein
- Agent Michael P. Morris; Edward S. Lazer
- Priority: EP08151842 20080222
- International Application: PCT/EP2009/001082 WO 20090217
- International Announcement: WO2009/103479 WO 20090827
- Main IPC: C07D265/00
- IPC: C07D265/00
Abstract:
This invention concerns a crystalline, enantiopure hydrochloride salt of N-(5-{2-[3-(4,4-diethyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-1,1-dimethyl-propylamino-1-hydroxy-ethyl}-2-hydroxy-phenyl)-methanesulfonamide, preferably of N-(5-{(R)-2-[3-(4,4-diethyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-1,1-dimethyl-propylamino-1-hydroxy-ethyl}-2-hydroxy-phenyl)-methanesulfonamide and its action as a long acting beta-agonist, alone or in combination with one or multiple other active ingredients for the treatment of respiratory diseases.
Public/Granted literature
- US20110262369A1 CRYSTALLINE, ENANTIOMERICALLY PURE SALT FORM OF A BETA-AGONIST, AND THE USE THEREOF AS A DRUG Public/Granted day:2011-10-27
Information query
